Orion - Company Announcement

Publishing of Orion Corporation's Interim Report for January-March 2015 on 29 April 2015

ORION CORPORATION     STOCK EXCHANGE RELEASE   16 APRIL 2015 at 11:00 A.M. EEST

Publishing of Orion Corporation's Interim Report for January-March 2015 on 29
April 2015


Orion will publish its Interim Report for January-March 2015 on Wednesday, 29
April 2015 approximately at 12:00 noon Finnish time (EEST). The release and
related presentation material in Finnish and in English will be available on the
Group's homepage at www.orion.fi/en/investors promptly after the publishing.
News conference for analysts and media

A news conference for analysts and media will be held on Wednesday 29 April
2015 at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki.
President and CEO Timo Lappalainen will give a brief presentation in English on
the financial review. Questions can be asked after the result presentation.

Participants should be prepared to present a photo ID on request.
Live webcast and conference call

A link to the live webcast will be available at Orion's website
www.orion.fi/en/investors.

The conference call ID is 952732 and the phone numbers to participate the
conference are:
Finland:          +358 (0)9 2313 9201
Sweden:         +46 (0)8 5052 0110
UK:                +44 (0)20 7162 0077
USA:              +1 334 323 6201

News conference recordings

A recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.
Silent period

The silent period preceding the publication is ongoing and continues until the
disclosure.


Orion Corporation



 Timo Lappalainen  Jari Karlson
 President and CEO CFO



Publisher:
Orion Corporation
www.orion.fi/en


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. The core therapy areas of Orion's pharmaceutical R&D are
central nervous system (CNS) disorders, oncology and respiratory for which Orion
developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2014 amounted to EUR 1,015 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.

[HUG#1911691]